Ekrem Yavuz

Ekrem Yavuz

Auto-generated profile, based on publicly available information

Ekrem Yavuz

Department of Pathology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Türkiye

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2011 in Oncology
Verified
Journal Article
Closed access
SKSerkan Keskin
Serkan Keskin
MMMahmut Muslumanoglu
Mahmut Muslumanoglu
PSPinar Saip
Pinar Saip
HKHasan Karanlık
Hasan Karanlık
MGMurat Guveli
Murat Guveli
ETErkan Topuz
Erkan Topuz
Objective: Patients with breast cancer with a pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) have a better prognosis than patients with residual disease. The aim of the current study was to identify predictors of pCR. Methods: This retrospective study included 388 patients treated with anthracycline-based NAC. Clinicopathological parameters were compared between the patients with and without pCR in breast and axilla. Results: Treatment consisted of FAC/FEC in 230 patients (59%), TAC in 39 (10%) patients and AC followed by docetaxel in 119 (31%). In all, 36 (9.3%) patients had pCR. In univariate analysis, age, tumor size, lymph node involvement, tumor grade (p = 0.077, n = 265), ER and HER-2 status (n = 213), lymphovascular invasion (LVI), type of chemotherapy and taxane-containing chemotherapy were associated with pCR. In multivariate analysis, ER negativity (p = 0.003), the absence of LVI (p = 0.009) and taxane-containing NAC (p = 0.026) were found to be significant indicators of pCR. Median follow-up time was 69 months. Progression-free survival was significantly improved in patients achieving pCR (p = 0.001). Conclusions: pCR is associated with a better outcome regardless of clinical and pathological parameters in breast cancer patients who receive NAC. The probability of pCR was higher in ER-negative, LVI-negative tumors and in patients treated with sequential taxane-containing chemotherapy.

1 April 2001 in Pathology International
Verified
Journal Article
Closed access
PDF file
RIRıdvan Ilhan
Rıdvan Ilhan
EYEkrem Yavuz
Ekrem Yavuz
AIAltan Iplikçi
Altan Iplikçi
STSıtkı Tuzlalı
Sıtkı Tuzlalı

6 December 2018 in International Journal of Surgical Pathology
Verified
Journal Article
Closed access
Mehmet GunduzMehmet Gunduz
Mehmet Gunduz
OHOzge Hurdogan
Ozge Hurdogan
SOSemen Onder
Semen Onder
EYEkrem Yavuz
Ekrem Yavuz
In this article, we present a case of anastomosing hemangioma that shows cystic change. The tumor was a unilocular cystic lesion consisting of 2 distinct layers. The inner layer was composed of a proliferation of capillary-sized blood vessels resembling red pulp of the spleen. The outer layer was composed of stromal cells that resembled Leydig or steroid cell tumor of the ovary. An immunohistochemical examination confirmed endothelial and stromal characteristics of the layers, respectively. An ultrastructural analysis revealed absence of Reinke crystalloids in the stromal cells. We conclude that anastomosing hemangioma may rarely arise from the ovary as a cystic tumor and may be accompanied with luteinization of stromal cells.

14 April 2025 in World Journal of Surgery
Verified
Journal Article
Open access
EÖEnver Özkurt
Enver Özkurt
Çetin OrduÇetin Ordu
Çetin Ordu
TÖTolga Özmen
Tolga Özmen
AIAhmet Serkan Ilgun
Ahmet Serkan Ilgun
GSGursel Soybir
Gursel Soybir
VÖVahit Özmen
Vahit Özmen
Introduction: Achieving a pCR serves as a biomarker indicating enhanced overall survival for breast cancer patients undergoing NST. Vitamin D enhances the antitumor effect of chemotherapeutics as demonstrated in cancer cells and animal models. In this prospective randomized clinical study, we aim to investigate the effect of oral vitamin D supplementation during neoadjuvant systemic therapy (NST) on pathologic complete response (pCR). Methods: Between June 2019 and June 2023, an oral form of 50,000 IU vitamin D3 (cholecalciferol) replacement was administered once a week during NST for the study group. Results: There were 114 (50.2%) cases in the study group and 113 (49.8%) in the control group (totally 227 cases). Factors that positively influenced pCR were higher clinical T stage, higher AJCC clinical stage, Estrogen receptor negativity, progesterone receptor negativity, human epidermal growth factor receptor 2 positivity, high Ki‐67 expression (≥ 20%), hormone negative molecular subtypes, and vitamin D intake in univariate analysis. In the multivariate analysis, factors significantly affecting pCR were vitamin D intake (OR: 2.33, 95% CI 1.20–4.53; p = 0.013), hormone receptor negativity (OR: 2.22, 95% CI 1.11–4.43; p = 0.024), and Ki‐67 ≥ 20% (OR: 3.27, 95% CI 1.03–10.34; p = 0.044). Conclusions: This is the first and only study to compare the effect of oral vitamin D supplementation on pCR during NST. Vitamin D supplementation during NST has a significant effect on pCR in breast cancer patients. Although this effect is not significant for axillary pCR, there is an almost significant correlation. Trial Registration: ClinicalTrials.gov (Identifier: NCT03986268)

29 June 2018 in European Journal of Breast Health
Verified
Journal Article
Closed access
TCTulay Canda
Tulay Canda
EYEkrem Yavuz
Ekrem Yavuz
NONecmettin Ozdemir
Necmettin Ozdemir
SISennur Ilvan
Sennur Ilvan
SSSerpil Dizbay Sak
Serpil Dizbay Sak
BGBurce Goktas
Burce Goktas
Objective: As patients with increased human epidermal growth factor receptor (HER2) overexpression are more likely to benefit from trastuzumab treatment, the accuracy of HER2 receptor status in breast cancer patients is significant for appropriate disease management. However, this assessment is not harmonized and results may be highly variable between centers. The aim of this study was to investigate the degree of interlaboratory variability in the results of HER2 expression reported by 5 participating centers and to assess the concordance between these centers and a reference laboratory. Materials and Methods: A total of 30 breast cancer samples were tested and scored for HER2 expression using immunohistochemical method in 5 centers from Turkey and in a reference laboratory from Netherlands (Academic Medical Center, Amsterdam). All the participating centers had an experience of more than 10 years regarding the HER2 testing. The results were compared both among the centers and with the reference laboratory. Results: When the concordance of participating centers and the reference laboratory was evaluated regarding negative (0-1+), equivocal 2(+) and positive 3(+) classification of HER2 immunostaining, the highest concordance was found in Center-A, and the lowest in Center-C (Kendall's tau-b concordance coefficient 0.911 and 0.724, respectively). The concordance of the centers with reference laboratory was 80.0% both in equivocal and positive samples, while it increased up to 91.8% in negative samples. Conclusions: This study showed that in general there is sufficiently good agreement between the reference laboratory and the participating centers for immunohistochemical HER2 assessment.

4 September 2025 in European Journal of Breast Health
Verified
Journal Article
Open access
PDF file
ABAysel Bayram
Aysel Bayram
SBSidar Bagbudar
Sidar Bagbudar
CKCagla Safak Karaoglan
Cagla Safak Karaoglan
ESEsma Sayar
Esma Sayar
BMBaran Mollavelioğlu
Baran Mollavelioğlu
EYEkrem Yavuz
Ekrem Yavuz
Accuracy of Intraoperative Sentinel Lymph Node Evaluation by Imprint Cytology in Breast Cancer: A 12-Year Single Center Experience With 2,528 Patients - European Journal of Breast Health